SEARCH:   Advanced

Blood, 1 July 2004, Vol. 104, No. 1, pp. 143-148. Prepublished online as a Blood First Edition Paper on March 16, 2004; DOI 10.1182/blood-2003-11-4085. This Article Full Text (PDF) All Versions of this Article: 2003-11-4085v1 104/1/143    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Brouwer, J.-L. P Articles by van der Meer, J. Search for Related Content PubMed PubMed Citation Articles by Brouwer, J.-L. P Articles by van der Meer, J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted December 1, 2003 Accepted February 28, 2004 The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus Jan-Leendert P Brouwer*, Marc Bijl, Nic J Veeger, Hanneke C Kluin-Nelemans, and Jan van der Meer Division of Haemostasis, Thrombosis and Rheology, Hematology, University Hospital Groningen, Groningen, The Netherlands Division of Haemostasis, Thrombosis and Rheology, Immunology, University Hospital Groningen, Groningen, The Netherlands Division of Haemostasis, Thrombosis and Rheology, Trial Coordination Centre, University Hospital Groningen, Groningen, The Netherlands * Corresponding author; email: j.l.p.brouwer{at}int.azg.nl. Systemic lupus erythematosus (SLE) is associated with an increased risk of venous (VTE) and arterial thromboembolism (ATE). Lupus anticoagulant (LA) and anticardiolipin antibodies (ACA) are established risk factors. We assessed the contribution of deficiencies of antithrombin, protein C, total protein S, factor V Leiden, the prothrombin G20210A mutation and APC resistance , either alone or in various combinations with LA and/ or ACA, to the thrombotic risk in a cohort of 144 consecutive SLE patients. Median follow-up was 12.7 years. VTE had occurred in 10% and ATE in 11% of patients. LA, ACA, factor V Leiden and the prothrombin mutation were identified as risk factors for VTE. Annual incidences of VTE were 2.01 (0.74-4.37) in patients with one of these disorders and 3.05 (0.63-8.93) in patients with two disorders. The risk of VTE was 20- and 30-fold higher, respectively, compared to the normal population. In contrast with LA and ACA, thrombophilic disorders did not influence the risk of ATE. In conclusion, factor V Leiden and the prothrombin mutation contribute to the risk of VTE in SLE patients, and potentiate this risk when one of these thrombophilic defects are combined with LA and/ or ACA. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Bertoli, L. Vila, G. Alarcon, G McGwin, J. Edberg, M Petri, R Ramsey-Goldman, J. Reveille, R. Kimberly, and for the PROFILE Study Group Factors Associated with Arterial Vascular Events in PROFILE: A Multiethnic Lupus Cohort Lupus, October 1, 2009; 18(11): 958 - 965. [Abstract] [PDF] A. DANOWSKI, M. N. L. de AZEVEDO, J. A. de SOUZA PAPI, and M. PETRI Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus J Rheumatol, June 1, 2009; 36(6): 1195 - 1199. [Abstract] [Full Text] [PDF] M. K. Farmer-Boatwright and R. A.S. Roubey Venous Thrombosis in the Antiphospholipid Syndrome Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 321 - 325. [Abstract] [Full Text] [PDF] W. M. Lijfering, R. Mulder, M. K. ten Kate, N. J. G. M. Veeger, A. B. Mulder, and J. van der Meer Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives Blood, February 5, 2009; 113(6): 1225 - 1230. [Abstract] [Full Text] [PDF] J. ROMERO-DIAZ, I. GARCIA-SOSA, and J. SANCHEZ-GUERRERO Thrombosis in Systemic Lupus Erythematosus and Other Autoimmune Diseases of Recent Onset J Rheumatol, January 1, 2009; 36(1): 68 - 75. [Abstract] [Full Text] [PDF] K de Leeuw, J Blaauw, A. Smit, C. Kallenberg, and M Bijl Vascular responsiveness in the microcirculation of patients with systemic lupus erythematosus is not impaired Lupus, November 1, 2008; 17(11): 1010 - 1017. [Abstract] [PDF] T. Avcin, R. Cimaz, E. D. Silverman, R. Cervera, M. Gattorno, S. Garay, Y. Berkun, F. R. Sztajnbok, C. A. Silva, L. M. Campos, et al. Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry Pediatrics, November 1, 2008; 122(5): e1100 - e1107. [Abstract] [Full Text] [PDF] M. Casato, M. Carlesimo, A. Francia, C. Timarco, A. Antenucci, M. Bove, H. Martini, M. Visentini, M. Fiorilli, and L. Conti Influence of inherited and acquired thrombophilic defects on the clinical manifestations of mixed cryoglobulinaemia Rheumatology, November 1, 2008; 47(11): 1659 - 1663. [Abstract] [Full Text] [PDF] H. L. Nienhuis, K. de Leeuw, J. Bijzet, A. Smit, C. G. Schalkwijk, R. Graaff, C. G. Kallenberg, and M. Bijl Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts Rheumatology, October 1, 2008; 47(10): 1554 - 1558. [Abstract] [Full Text] [PDF] G. W. Moore, S. Rangarajan, and G. F. Savidge The Activated Seven Lupus Anticoagulant Assay Detects Clinically Significant Antibodies Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 332 - 337. [Abstract] [PDF] W. M. Lijfering, H. G. Sprenger, R. R. Georg, P. A. van der Meulen, and J. van der Meer Relationship between Progression to AIDS and Thrombophilic Abnormalities in HIV Infection Clin. Chem., July 1, 2008; 54(7): 1226 - 1233. [Abstract] [Full Text] [PDF] K. de Leeuw, R. Graaff, R. de Vries, R. P. Dullaart, A. J. Smit, C. G. Kallenberg, and M. Bijl Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus Rheumatology, October 1, 2007; 46(10): 1551 - 1556. [Abstract] [Full Text] [PDF] Z. Touma, S. Atweh, L. Kibbi, and T. Arayssi Longitudinal myelitis in patient with systemic lupus erythematosus, homozygous prothrombin G20210A and heterozygous MTHFR 677T Lupus, July 1, 2007; 16(7): 517 - 520. [Abstract] [PDF] T. Lecompte, D. Wahl, C. Perret-Guillaume, H. C. Hemker, P. Lacolley, and V. Regnault Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk Haematologica, May 1, 2007; 92(5): 714 - 715. [Abstract] [Full Text] [PDF] K De Leeuw, B Freire, A J Smit, H Bootsma, C G Kallenberg, and M Bijl Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus Lupus, October 1, 2006; 15(10): 675 - 682. [Abstract] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020